SEC Tracker
Get the app

Dyne Therapeutics DYN

Dyne Therapeutics reported a net loss of $193.55 million for Q3 2026

Form
10-Q
Filed
Importance
Notable
  1. Net loss: $193.55 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$1.06 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $913.2 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Dyne Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

  • For the quarter ended September 30, 2026, Dyne Therapeutics, Inc. reported: Net income -$193.6 million.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Akebia Therapeutics AKBA public float $946M, Jun 30, 2025
  2. Viridian Therapeutics VRDN public float $943M, Jun 30, 2025
  3. Collegium Pharmaceutical COLL public float $926M, Jun 30, 2025
  4. Neogen NEOG public float $972M, Nov 30, 2025
  5. Ardelyx ARDX public float $924M, Jun 30, 2025